Apixaban Intermediate CAS 545445-44-1 Purity >98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 3-Morpholino-1-(4-(2-Oxopiperidin-1-yl)phenyl)-5,6-Dihydropyridin-2(1H)-one (CAS: 545445-44-1) with high quality, intermediate of Apixaban (CAS: 503612-47-3). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Apixaban Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | 3-Morpholino-1-(4-(2-Oxopiperidin-1-yl)phenyl)-5,6-Dihydropyridin-2(1H)-one |
| Synonyms | Apixaban Intermediate 1; 5,6-Dihydro-3-(4-Morpholinyl)-1-[4-(2-Oxo-1-Piperidinyl)phenyl]-2(1H)-Pyridinone; 5-Morpholin-4-yl-1-[4-(2-Oxopiperidin-1-yl)phenyl]-2,3-Dihydropyridin-6-one; Apixaban Impurity A |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 545445-44-1 |
| Molecular Formula | C20H25N3O3 |
| Molecular Weight | 355.43 g/mol |
| Melting Point | >199℃(dec.) |
| Density | 1.267 g/mL |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Apixaban (CAS: 503612-47-3) |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | Light Yellow Powder | Light Yellow Powder |
| Loss on Drying | <0.50% | 0.16% |
| Residue on Ignition | <0.20% | 0.07% |
| Purity / Analysis Method | >98.0% (HPLC Area) | 99.12% |
| Any Individual Impurity | <0.50% | <0.50% |
| Total Impurities | <2.00% | 0.88% |
| 1H NMR Spectrum | Consistent with Structure | Conforms |
| LC-MS for Identification | Conforms | Conforms |
| Conclusion | The product has been tested and complies with the given specifications | |
| Application | Intermediate of Apixaban (CAS: 503612-47-3) | |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
3-Morpholino-1-(4-(2-Oxopiperidin-1-yl)phenyl)-5,6-Dihydropyridin-2(1H)-one (CAS: 545445-44-1) is an intermediate of Apixaban (CAS: 503612-47-3).
Apixaban is a new type of oral Xa factor inhibitor jointly developed by Bristol-Myers Squibb and Pfizer. The trade name is Eratol, which is a new type of oral anticoagulant. By inhibiting an important coagulation factor Xa, Apixaban can prevent thrombin production and thrombosis. On April 26, 2007, Bristol-Myers Squibb joined hands with Pfizer to announce the cooperation in the development of a new oral anticoagulant Apixaban owned by Bristol-Myers Squibb as an upgraded alternative to Warfarin. In May 2011, Apixaban was the first to approve the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway. On November 20, 2012, the European Commission approved Ererto (Apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors. Subsequently, the Canadian Food and Drug Administration, Japan, and the US FDA approved Ererto (Apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors. On April 12, 2013, the new anticoagulant drug Eloto (ELIQUIS)(Apixaban) jointly developed by Bristol-Myers Squibb and Pfizer was officially announced to be listed in China.
![Apixaban Intermediate CAS 27143-07-3 Ethyl Chloro[(4-Methoxyphenyl)hydrazono]acetate Purity ≥99.0% (HPLC)](https://www.ruifuchem.com/uploads/Apixaban-Intermediate-CAS-490-46-0-Factory-Shanghai-Ruifu-Chemical-Co.-Ltd.-www.ruifuchem.com_-300x300.jpg)
